Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Cardiff Oncology Inc (NASDAQ: CRDF) closed the day trading at $2.64 up 11.39% from the previous closing price of $2.37. In other words, the price has increased by $11.39 from its previous closing price. On the day, 5.86 million shares were traded. CRDF stock price reached its highest trading level at $2.79 during the session, while it also had its lowest trading level at $2.4.
Ratios:
For a better understanding of CRDF, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.42 and its Current Ratio is at 4.42. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on July 08, 2025, initiated with a Buy rating and assigned the stock a target price of $19.
On June 24, 2025, Jefferies started tracking the stock assigning a Hold rating and target price of $3.50.
On September 06, 2024, Craig Hallum started tracking the stock assigning a Buy rating and target price of $8.Craig Hallum initiated its Buy rating on September 06, 2024, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 30 ’25 when PACE GARY W bought 275,000 shares for $2.45 per share. The transaction valued at 673,750 led to the insider holds 1,330,676 shares of the business.
PACE GARY W bought 15,000 shares of CRDF for $36,750 on Jul 30 ’25. The Director now owns 1,345,676 shares after completing the transaction at $2.45 per share. On Dec 17 ’24, another insider, Levine James E., who serves as the Chief Financial Officer of the company, bought 2,752 shares for $5.42 each. As a result, the insider paid 14,905 and bolstered with 65,316 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 175628384 and an Enterprise Value of 105856256. For the stock, the TTM Price-to-Sale (P/S) ratio is 319.33 while its Price-to-Book (P/B) ratio in mrq is 3.00. Its current Enterprise Value per Revenue stands at 194.232 whereas that against EBITDA is -1.962.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.54, which has changed by 0.27536237 over the last 52 weeks, in comparison to a change of 0.20277917 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $5.64, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is -26.15%, while the 200-Day Moving Average is calculated to be -23.46%.
Shares Statistics:
Over the past 3-months, CRDF traded about 1.67M shares per day on average, while over the past 10 days, CRDF traded about 4838600 shares per day. A total of 66.53M shares are outstanding, with a floating share count of 60.47M. Insiders hold about 8.68% of the company’s shares, while institutions hold 43.94% stake in the company. Shares short for CRDF as of 1752537600 were 18896208 with a Short Ratio of 11.30, compared to 1749772800 on 17289872. Therefore, it implies a Short% of Shares Outstanding of 18896208 and a Short% of Float of 29.160000000000004.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
